代谢相关脂肪性肝病与胰腺癌相关性的研究进展
Research Progress on the Relationship between Metabolic-Associated Fatty Liver Disease and Pancreatic Cancer
DOI: 10.12677/ACM.2023.134895, PDF,   
作者: 邹 渠, 杨 慷*：重庆医科大学附属第二医院肝胆外科，重庆
关键词: 代谢相关脂肪性肝病；胰腺癌；相关性；Metabolic-Associated Fatty Liver Disease； Pancreatic Cancer； Relevance
摘要: 2020年，非酒精性脂肪性肝病(NAFLD)已更名为代谢相关脂肪性肝病(MAFLD)，它是世界上慢性肝病最常见的原因。胰腺癌是MAFLD肝外常见的并发症之一。近年来，大量研究显示MAFLD患者发生胰腺癌的风险较高，其中机制尚未完全明确，可能与炎症反应、肠道菌群等因素有关。本文综述MAFLD和胰腺癌的相关性，以期为预测MAFLD和胰腺癌的发病及治疗提供帮助。
Abstract: In 2020, non-alcoholic fatty liver disease (NAFLD) has been renamed metabolic-associated fatty liv-er disease (MAFLD), which is the most common cause of chronic liver disease in the world. Pancre-atic cancer is one of the common extrahepatic complications of MAFLD. In recent years, a large number of studies have shown that patients with MAFLD have a higher risk of pancreatic cancer, and the mechanism has not been fully understood, which may be related to inflammatory reaction, intestinal flora and other factors. This article reviews the correlation between MAFLD and pancre-atic cancer in order to provide help for predicting the incidence and treatment of MAFLD and pan-creatic cancer.
文章引用：邹渠, 杨慷. 代谢相关脂肪性肝病与胰腺癌相关性的研究进展[J]. 临床医学进展, 2023, 13(4): 6369-6373. https://doi.org/10.12677/ACM.2023.134895

参考文献

[1] Eslam, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
[2] Younossi, Z., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20. [Google Scholar] [CrossRef] [PubMed]
[3] Younossi, Z., et al. (2019) Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 69, 2672-2682. [Google Scholar] [CrossRef] [PubMed]
[4] Estes, C., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepa-tology, 69, 896-904. [Google Scholar] [CrossRef] [PubMed]
[5] Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[6] Cai, J., et al. (2021) Advances in the Epidemiology of Pancreatic Cancer: Trends, Risk Factors, Screening, and Prognosis. Cancer Letters, 520, 1-11. [Google Scholar] [CrossRef] [PubMed]
[7] Hu, J.X., et al. (2021) Pancreatic Cancer: A Review of Epidemi-ology, Trend, and Risk Factors. World Journal of Gastroenterology, 27, 4298-4321. [Google Scholar] [CrossRef] [PubMed]
[8] Zhao, Z. and Liu, W. (2020) Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technology in Cancer Research & Treatment. [Google Scholar] [CrossRef] [PubMed]
[9] Byrne, C.D. and Targher, G. (2015) NAFLD: A Multisystem Disease. Journal of Hepatology, 62, S47-S64. [Google Scholar] [CrossRef] [PubMed]
[10] Diehl, A.M. and Day, C. (2017) Cause, Pathogenesis, and Treat-ment of Nonalcoholic Steatohepatitis. The New England Journal of Medicine, 377, 2063-2072. [Google Scholar] [CrossRef] 
[11] Mitsala, A., et al. (2022) Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing? Current Oncology, 29, 4478-4510. [Google Scholar] [CrossRef] [PubMed]
[12] Rezende, A.Q.M., et al. (2021) Is There a Link between Non-Alcoholic Fatty Liver Disease Aspects and Pancreatic Cancer? Results of a Case-Matched Study. Revista do Colégio Brasileiro de Cirurgiões, 48, e20202913. [Google Scholar] [CrossRef] [PubMed]
[13] Allen, A.M., et al. (2019) The Risk of Incident Extrahepatic Cancers Is Higher in Non-Alcoholic Fatty Liver Disease than Obesity—A Longitudinal Cohort Study. Journal of Hepa-tology, 71, 1229-1236. [Google Scholar] [CrossRef] [PubMed]
[14] Park, J.H., et al. (2022) Increased Risk of Pancreatic Cancer in In-dividuals with Non-Alcoholic Fatty Liver Disease. Scientific Reports, 12, Article No. 10681. [Google Scholar] [CrossRef] [PubMed]
[15] Simon, T.G., et al. (2021) Cancer Risk in Patients with Biop-sy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology, 74, 2410-2423. [Google Scholar] [CrossRef] [PubMed]
[16] Kim, G.A., et al. (2017) Association between Non-Alcoholic Fatty Liver Disease and Cancer Incidence Rate. Journal of Hepatology.
[17] Alessandro Mantovani, M., Petracca, G., Beatrice, G., et al. (2022) Non‐Alcoholic Fatty Liver Disease and Increased Risk of Incident Extra‐Hepatic Cancers: A Meta‐Analysis of Observational Cohort Studies. Gut, 71, 778-788. [Google Scholar] [CrossRef] [PubMed]
[18] Colotta, F., et al. (2009) Cancer-Related Inflammation, the Sev-enth Hallmark of Cancer: Links to Genetic Instability. Carcinogenesis, 30, 1073-1081. [Google Scholar] [CrossRef] [PubMed]
[19] Ren, R., et al. (2019) Inflammation Promotes Progression of Pancreatic Cancer through WNT/beta-Catenin Pathway- Dependent Manner. Pancreas, 48, 1003-1014. [Google Scholar] [CrossRef] 
[20] Zhang, Y., et al. (2013) Canonical WNT Signaling Is Re-quired for Pancreatic Carcinogenesis. Cancer Research, 73, 4909-4922. [Google Scholar] [CrossRef] 
[21] Tao, M., et al. (2016) Inflammatory Stimuli Promote Growth and Invasion of Pancreatic Cancer Cells through NF- kappaB Pathway Dependent Repression of PP2Ac. Cell Cycle, 15, 381-393. [Google Scholar] [CrossRef] [PubMed]
[22] Alberto Villanueva, C.G., Paules, A.B., Vicente, M., et al. (1998) Disruption of the Antiproliferative TGF-b Signaling Pathways in Human Pancreatic Cancer Cells. Oncogene, 17, 1969-1978. [Google Scholar] [CrossRef] [PubMed]
[23] Feng, H.Y. and Chen, Y.C. (2016) Role of Bile Acids in Carcinogenesis of Pancreatic Cancer: An Old Topic with New Perspective. World Journal of Gastroenterology, 22, 7463-7477. [Google Scholar] [CrossRef] [PubMed]
[24] Režen, T., Rozman, D., Kovács, T., Kovács, P., Sipos, A., Bai, P. and Mikó, E. (2022) The Role of Bile Acids in Carcinogenesis. Cellular and Molecular Life Sciences, 79, 243. [Google Scholar] [CrossRef] [PubMed]
[25] Leung, C., et al. (2016) The Role of the Gut Microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology, 13, 412-425. [Google Scholar] [CrossRef] [PubMed]
[26] Wei, M.Y., et al. (2019) The Microbiota and Microbiome in Pancre-atic Cancer: More Influential than Expected. Molecular Cancer, 18, 97. [Google Scholar] [CrossRef] [PubMed]
[27] Paul, J. and Shihaz, A.V.H. (2020) Pancreatic Steatosis: A New Diagnosis and Therapeutic Challenge in Gastroenterology. Arquivos de Gastroenterologia, 57, 216-220. [Google Scholar] [CrossRef] [PubMed]
[28] Chang, M.L. (2022) Fatty Pancreas-Centered Metabolic Basis of Pancreatic Adenocarcinoma: From Obesity, Diabetes and Pancreatitis to Oncogenesis. Biomedicines, 10, 692. [Google Scholar] [CrossRef] [PubMed]
[29] Bugianesi, E., et al. (2010) Insulin Resistance in Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 16, 1941-1951. [Google Scholar] [CrossRef] [PubMed]

为你推荐